Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma

BackgroundTo evaluate the efficacy and safety of everolimus, a mTOR inhibitor, on invasive malignant renal epithelioid angiomyolipoma (EAML).Materials and MethodsFrom Oct 2014 to May 2019, we collected data from seven patients with a definite (clinical and pathological) diagnosis of EAML received ev...

Full description

Bibliographic Details
Main Authors: Gang Guo, Liangyou Gu, Xu Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
renal epithelioid angiomyolipoma
everolimus
tuberous sclerosis complex
mutation
next-generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.610858/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.610858/full

Similar Items